起重机监控器双机协同中CAN总线的应用

为了满足工程建设日益大型化的发展,两台以及多台起重机共同作业的需求日益增强。设定了起重机双机协同模型,使用飞思忙尔MC9S12DGl28单片机以实现起重机监控器的双机协同功能,设计了CAN总线节点模块来实现双机的数据采集、状态检测和故障处理等功能,给出了实现双机协同的硬件设计和软件流程图。系统在实际运行过程中稳定、可靠,能保证起重机在双机协同时做到步调一致,并很好地应对故障的发生,同时表明CAN总线在起重机工作环境中能够很好地发挥自身通讯距离长、抗干扰能力强等优势,符合了双机协同的功能要求。     

基于GPRS和Web远程管理系统的设备监控终端设计

以STC12C5A32S2为核心,基于GPRS无线通信网络和Web远程控制技术,设计了一套设备监控系统终端,实现对被监控设备进行远程监控与数据采集,将数据上传至远端的Web管理系统进行数据管理,解决了对大量终端设备的远程实时监控和通信问题。     

基于ADE7755的单相电子式电能表设计

单相电子式电能表以单片机ATmega128作为核心控制芯片,采用高精度电能计量芯片ADE7755采集电量,实现电能计量、电价分时段计算、电量存储和显示、RS485和红外通信等功能。本文介绍了电能表的硬件组成和功能模块的作用,给出了电能计量模块、RS485和红外通信模块的硬件原理图,给出了主程序流程图。经实验测试,该电能表的技术指标符合IEC62053-21标准。     

基于增量式PID算法的帆板控制系统的设计

基于STC12C5A60S2单片机与增量式PID算法,实现对帆板系统的控制。该系统主要由键盘模块、显示模块、风扇驱动模块、角度测量模块、报警模块组成。角度传感器测量帆板的角度并反馈回单片机,通过增量式PID算法计算,并由PWM方法控制风扇的转速,从而实现精确控制风扇风力与帆板角度。     

基于ATmega128单片机的汽车太阳能充电控制器

利用车上太阳能电池驱动换风扇并作为汽车电瓶辅助充电电源。由ATmega128为核心构成太阳能电池驱动换风扇和电瓶充电的控制系统。这个控制器测量车内外温度、太阳能电池电压、汽车电瓶电压,根据车内外温差自动控制换气风扇工作,根据太阳能电池输出状态和电瓶状态控制充电过程。最后,基于给出的软硬件设计构建了实验系统,进行了实验和总结。     

纯电动汽车太阳能辅助空调控制系统的硬件设计

纯电动汽车车载动力电池是其唯一的动力源且很有限,辅助设备消耗的电能减少了纯电动汽车的续驶里程,尤其是空调,所以开发高效的纯电动汽车空调系统是纯电动汽车能够被市场接受的关键。将纯电动汽车顶盖布满太阳电池,可以使空调系统的制冷能力增强,同时还能增加纯电动汽车的行驶距离。对小型纯电动汽车的太阳能辅助空调系统进行研究,设计出适合该空调的自动控制系统,可为纯电动汽车创造出一个更加舒适的驾驶和乘座环境。     

NH4SCN从ROH-CTMAB-C12H26载金有机相中反萃金

研究了硫氰酸铵（NH4SCN）从混合醇（ROH）－十六烷基三甲基溴化铵（CTMAB）－正十二烷（C12H26）载金有机相中反萃金，考察了平衡时间，PH值，反萃剂浓度，温度等因素对反萃率的影响及有机相的循环使用，绘制了反萃等温曲线，结果表明，NH4SCN对金具有较高反萃率，可顺利实现金的反萃。     

Distinct Expression Patterns of Cxcl12 in Mesenchymal Stem Cell Niches of Intact and Injured Rodent Teeth

Specific stem cell populations within dental mesenchymal tissues guarantee tooth homeostasis and regeneration throughout life. The decision between renewal and differentiation of stem cells is greatly influenced by interactions with stromal cells and extracellular matrix molecules that form the tissue specific stem cell niches. The Cxcl12 chemokine is a general marker of stromal cells and plays fundamental roles in the maintenance, mobilization and migration of stem cells. The aim of this study was to exploit Cxcl12-GFP transgenic mice to study the expression patterns of Cxcl12 in putative dental niches of intact and injured teeth. We showed that endothelial and stromal cells expressed Cxcl12 in the dental pulp tissue of both intact molars and incisors. Isolated non-endothelial Cxcl12⁺ dental pulp cells cultured in different conditions in vitro exhibited expression of both adipogenic and osteogenic markers, thus suggesting that these cells possess multipotent fates. Taken together, our results show that Cxcl12 is widely expressed in intact and injured teeth and highlight its importance as a key component of the various dental mesenchymal stem cell niches.     

If Virchow and Ehrlich Had Dreamt Together: What the Future Holds for KRAS-Mutant Lung Cancer

Non-small-cell lung cancer (NSCLC) with Kirsten rat sarcoma (KRAS) mutations has notoriously challenged oncologists and researchers for three notable reasons: (1) the historical assumption that KRAS is “undruggable”, (2) the disease heterogeneity and (3) the shaping of the tumor microenvironment by KRAS downstream effector functions. Better insights into KRAS structural biochemistry allowed researchers to develop direct KRAS(G12C) inhibitors, which have shown early signs of clinical activity in NSCLC patients and have recently led to an FDA breakthrough designation for AMG-510. Following the approval of immune checkpoint inhibitors for PDL1-positive NSCLC, this could fuel yet another major paradigm shift in the treatment of advanced lung cancer. Here, we review advances in our understanding of the biology of direct KRAS inhibition and project future opportunities and challenges of dual KRAS and immune checkpoint inhibition. This strategy is supported by preclinical models which show that KRAS(G12C) inhibitors can turn some immunologically “cold” tumors into “hot” ones and therefore could benefit patients whose tumors harbor subtype-defining STK11/LKB1 co-mutations. Forty years after the discovery of KRAS as a transforming oncogene, we are on the verge of approval of the first KRAS-targeted drug combinations, thus therapeutically unifying Paul Ehrlich’s century-old “magic bullet” vision with Rudolf Virchow’s cancer inflammation theory.     

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus

Blood platelets’ adenosine receptors (AR) are considered to be a new target for the anti-platelet therapy. This idea is based on in vitro studies which show that signaling mediated by these receptors leads to a decreased platelet response to activating stimuli. In vivo evidence for the antithrombotic activity of AR agonists published to date were limited, however, to the usage of relatively high doses given in bolus. The present study was aimed at verifying if these substances used in lower doses in combination with inhibitors of P2Y₁₂ could serve as components of dual anti-platelet therapy. We have found that a selective A_2A agonist 2-hexynyl-5’-N-ethylcarboxamidoadenosine (HE-NECA) improved the anti-thrombotic properties of either cangrelor or prasugrel in the model of ferric chloride-induced experimental thrombosis in mice. Importantly, HE-NECA was effective not only when applied in bolus as other AR agonists in the up-to-date published studies, but also when given chronically. In vitro thrombus formation under flow conditions revealed that HE-NECA enhanced the ability of P2Y₁₂ inhibitors to decrease fibrinogen content in thrombi, possibly resulting in their lower stability. Adenosine receptor agonists possess a certain hypotensive effect and an ability to increase the blood–brain barrier permeability. Therefore, the effects of anti-thrombotic doses of HE-NECA on blood pressure and the blood–brain barrier permeability in mice were tested. HE-NECA applied in bolus caused a significant hypotension in mice, but the effect was much lower when the substance was given in doses corresponding to that obtained by chronic administration. At the same time, no significant effect of HE-NECA was observed on the blood–brain barrier. We conclude that chronic administration of the A_2A agonist can be considered a potential component of a dual antithrombotic therapy. However, due to the hypotensive effect of the substances, dosage and administration must be elaborated to minimize the side-effects. The total number of animals used in the experiments was 146.